Signal mining of adverse drug events related to hypovolemia caused by SGLT2 inhibitors based on FAERS database
Authors:
Open Access
- 20 June 2025
- journal article
- research article
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 46 (1) , 323-333
Abstract
Background: Hypovolemia is one of the most common adverse events (AE) of SGLT2is, which is overlooked, especially in the elderly population. Objective: In this study, signal mining of AEs caused by SGLT2is was conducted, and the AE signals related to hypovolemia in the real world after marketing were statistically analyzed, so as to provide reference for reducing AEs and for clinical rational drug use. Methods: The FDA adverse event reporting system (FAERS) is an important data source for spontaneous reporting of AEs. A total of 46 quarterly data from 2013 Q1 to 2024 Q2 was extracted for analysis. In this study, disproportionality analysis was used to detect the signals of AEs and four methods including ROR, MHRA, BCPNN, and MGPS were combined. Results: 5017 AE reports related to SGLT2is induced hypovolemia were included in the analysis. According to the ROR value of signal mining, empagliflozin had a higher risk of hypovolemia (ROR = 13.87), while canagliflozin had a higher risk of hypovolemic shock (ROR = 3.40). In stratification analysis by sex, the risk of hypovolemia-related AEs was higher in females using canagliflozin than in males. The most significant differences were hypovolaemia (female ROR = 10.98 vs. male ROR = 5.56). When stratified by age, it showed that patients < 18 years old, 18–44 years old, and > 75 years old had a higher risk of hypovolemia-related AEs than other age groups. Conclusions: Hypovolemia related AEs caused by SGLT2is were found to be more common in women and elderly patients.Keywords
Funding Information
- Key Laboratory Construction Project of Guangzhou Science and Technology (2023A03J0566)
This publication has 41 references indexed in Scilit:
- Association between sodium-glucose cotransporter-2 inhibitor and adverse events in patients with moderate to severe chronic kidney disease: a systematic review and meta-analysis of randomized controlled trialsEuropean Journal of Clinical Pharmacology, 2024
- Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysisAmerican Heart Journal Plus: Cardiology Research and Practice, 2023
- Physiology of Human Hemorrhage and Compensation2021
- Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Systematic Review and Meta-AnalysisESC Heart Failure, 2020
- SGLT2 inhibitors, sodium and off-target effects: an overviewJournal Of Nephrology, 2020
- SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into PracticeDiabetes Therapy, 2019
- Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensivesJournal of the American Society of Hypertension, 2016
- Hypohydration and Human Performance: Impact of Environment and Physiological MechanismsSports Medicine, 2015
- Orthostatic HypotensionJACC, 2015
- Dissociation between cortical activation and cognitive performance under pharmacological blood pressure elevation in chronic hypotensionBiological Psychology, 2007